Oil Prices Slip as Hormuz Shipping Progress and Rising U.S. Crude Stocks Weigh on Market 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
US Job Growth Seen Picking Up in July 
BOJ Rate Hike Expectations Rise Ahead of September Meeting 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Australia Trade Surplus Returns in June as Iron Ore, Coal and LNG Exports Surge 
Philippine GDP Growth Slows to 2.3% in Q2 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Asian Currencies Steady as Markets Await U.S. Jobs Data 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
